
Moderna, Inc.: shareholders and insiders
Price
$199.33
November 19, 2026Market cap $78.7B
What Ploutos Investor adds for Moderna
Part of Ploutos Investor, €9.99 a month
- The full history: 10 fiscal years, from 2016
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 23% since Nov 6, 2026, when the 10-Q these figures come from was filed ($254.19 then, $196.79 on Nov 18, 2026). The figures date from before that move.10-Q
Insiders and their shares
Purchases and sales by officers and directors from Nov 20, 2025 to Nov 18, 2026, from their own Form 4 filings.
Bought on the market
–
nobody
Sold on the market
$99M
6 people
From Nov 20, 2025 to Nov 20, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan99%
- The rest1%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 20, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·no buys·sold $98M by 6 people
- 2025: no buys, sold $717.3K by 2 people
- 2026: no buys, sold $98M by 6 people
- Nov 17, 2026Stephen HogePresidentKind10b5-1
- Nov 17, 2026Stephen HogePresidentKind10b5-1
- Nov 17, 2026Stephen HogePresidentKind10b5-1
- Nov 17, 2026Stephen HogePresidentKind10b5-1
- Nov 16, 2026Stephen HogePresidentKind10b5-1
- Nov 16, 2026Stephen HogePresidentKind10b5-1
- Nov 16, 2026Stephen HogePresidentKind10b5-1
- Oct 15, 2026Stephen HogePresidentKind10b5-1
- Oct 15, 2026Stephen HogePresidentKind10b5-1
- Oct 14, 2026Stephen HogePresidentKind10b5-1
- Oct 14, 2026Stephen HogePresidentKind10b5-1
- Oct 14, 2026Stephen HogePresidentKind10b5-1
- Oct 5, 2026James M MockChief Financial OfficerKind
- Oct 5, 2026James M MockChief Financial OfficerKind
- Sep 15, 2026Stephen HogePresidentKind10b5-1
- Sep 15, 2026Stephen HogePresidentKind10b5-1
- Sep 14, 2026Stephen HogePresidentKind10b5-1
- Sep 14, 2026Stephen HogePresidentKind10b5-1
- Sep 10, 2026James M MockChief Financial OfficerKind10b5-1
- Sep 10, 2026James M MockChief Financial OfficerKind10b5-1
- Sep 10, 2026James M MockChief Financial OfficerKind10b5-1
- Sep 4, 2026James M MockChief Financial OfficerKind
- Sep 4, 2026James M MockChief Financial OfficerKind
- Sep 4, 2026Shannon Thyme KlingerChief Legal OfficerKind
- Sep 4, 2026Shannon Thyme KlingerChief Legal OfficerKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 17, 2026 | Stephen HogePresident | 10b5-1 | 76.5K | $12.21 | $933.5K | Form 4 |
| Nov 17, 2026 | Stephen HogePresident | 10b5-1 | 34.0K | $211.45 | $7.2M | Form 4 |
| Nov 17, 2026 | Stephen HogePresident | 10b5-1 | 5,082 | $212.57 | $1.1M | Form 4 |
| Nov 17, 2026 | Stephen HogePresident | 10b5-1 | 157 | $214.19 | $33.6K | Form 4 |
| Nov 16, 2026 | Stephen HogePresident | 10b5-1 | 76.5K | $12.21 | $933.5K | Form 4 |
| Nov 16, 2026 | Stephen HogePresident | 10b5-1 | 39.2K | $219.66 | $8.6M | Form 4 |
| Nov 16, 2026 | Stephen HogePresident | 10b5-1 | 400.0K | – | – | Form 4 |
| Oct 15, 2026 | Stephen HogePresident | 10b5-1 | 76.5K | $12.21 | $933.5K | Form 4 |
| Oct 15, 2026 | Stephen HogePresident | 10b5-1 | 39.1K | $220.72 | $8.6M | Form 4 |
| Oct 14, 2026 | Stephen HogePresident | 10b5-1 | 76.5K | $12.21 | $933.5K | Form 4 |
| Oct 14, 2026 | Stephen HogePresident | 10b5-1 | 38.8K | $213.47 | $8.3M | Form 4 |
| Oct 14, 2026 | Stephen HogePresident | 10b5-1 | 450 | $214.15 | $96.4K | Form 4 |
| Oct 5, 2026 | James M MockChief Financial Officer | 1,454 | – | – | Form 4 | |
| Oct 5, 2026 | James M MockChief Financial Officer | 704 | $190.01 | $133.8K | Form 4 | |
| Sep 15, 2026 | Stephen HogePresident | 10b5-1 | 76.5K | $12.21 | $933.5K | Form 4 |
| Sep 15, 2026 | Stephen HogePresident | 10b5-1 | 40.3K | $146.07 | $5.9M | Form 4 |
| Sep 14, 2026 | Stephen HogePresident | 10b5-1 | 76.5K | $12.21 | $933.5K | Form 4 |
| Sep 14, 2026 | Stephen HogePresident | 10b5-1 | 40.3K | $144.13 | $5.8M | Form 4 |
| Sep 10, 2026 | James M MockChief Financial Officer | 10b5-1 | 19.8K | $30.96 | $614.1K | Form 4 |
| Sep 10, 2026 | James M MockChief Financial Officer | 10b5-1 | 19.8K | $134.49 | $2.7M | Form 4 |
| Sep 10, 2026 | James M MockChief Financial Officer | 10b5-1 | 15.0K | $134.49 | $2.0M | Form 4 |
| Sep 4, 2026 | James M MockChief Financial Officer | 11.8K | – | – | Form 4 | |
| Sep 4, 2026 | James M MockChief Financial Officer | 5,704 | $148.87 | $849.2K | Form 4 | |
| Sep 4, 2026 | Shannon Thyme KlingerChief Legal Officer | 11.8K | – | – | Form 4 | |
| Sep 4, 2026 | Shannon Thyme KlingerChief Legal Officer | 5,704 | $148.87 | $849.2K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before May 29, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by MRNA's officers and directors from 2019 up to November 19, 2025, 7 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 2 more, back to 2019
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- FMRwith 1 more personShare of class14.8%
- Vanguard Capital ManagementShare of class6.53%
- Capital World InvestorsShare of class5.60%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| FMRwith 1 more person | 14.8% | 58.93M | Nov 5, 20266 filings since May 12, 2025 | 13G/A | |
| Vanguard Capital Management | 6.53% | 25.93M | Apr 30, 2026 | 13G | |
| Capital World Investors | 5.60% | 22.28M | Aug 12, 2026 | 13G |
Fell to 5% or less (2)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Millennium Mgmt (Englander)In the quarter+788%
- Bridgewater (Dalio)In the quarter+528%
- Point72 (Cohen)In the quarter
- Citadel Advisors (Griffin)In the quarter-61%
- AQR CapitalIn the quarter-54%
- D.E. ShawIn the quarter+4.9%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Millennium Mgmt (Englander) | 3.89M | +788% | $750M | 0.55% |
| Bridgewater (Dalio) | 72.3K | +528% | $14M | 0.06% |
| Point72 (Cohen) | 108.6K | $21M | 0.03% | |
| Citadel Advisors (Griffin) | 116.2K | -61% | $22M | 0.01% |
| AQR Capital | 222.0K | -54% | $42M | 0.01% |
| D.E. Shaw | 26.2K | +4.9% | $5.0M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 8.26% of its shares outstanding were held short, +5.6% since the report before.
- Shares held short
- 32.60M
- 8.26%
- Since the report before30.86M on Sep 30, 2026
- +5.6%
- 1.8
- 18.29M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 22%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 19.61M
- Nov 15, 2023: Shares held short 22.38M
- Nov 30, 2023: Shares held short 21.99M
- Dec 15, 2023: Shares held short 21.88M
- Dec 29, 2023: Shares held short 24.19M
- Jan 12, 2024: Shares held short 23.07M
- Jan 31, 2024: Shares held short 20.88M
- Feb 15, 2024: Shares held short 24.08M
- Feb 29, 2024: Shares held short 22.11M
- Mar 15, 2024: Shares held short 22.23M
- Mar 28, 2024: Shares held short 21.44M
- Apr 15, 2024: Shares held short 20.98M
- Apr 30, 2024: Shares held short 21.07M
- May 15, 2024: Shares held short 21.43M
- May 31, 2024: Shares held short 20.18M
- Jun 14, 2024: Shares held short 21.60M
- Jun 28, 2024: Shares held short 22.13M
- Jul 15, 2024: Shares held short 22.74M
- Jul 31, 2024: Shares held short 22.59M
- Aug 15, 2024: Shares held short 25.00M
- Aug 30, 2024: Shares held short 25.63M
- Sep 13, 2024: Shares held short 27.61M
- Sep 30, 2024: Shares held short 31.32M
- Oct 15, 2024: Shares held short 33.26M
- Oct 31, 2024: Shares held short 34.38M
- Nov 15, 2024: Shares held short 39.86M
- Nov 29, 2024: Shares held short 40.84M
- Dec 13, 2024: Shares held short 39.49M
- Dec 31, 2024: Shares held short 37.85M
- Jan 15, 2025: Shares held short 43.01M
- Jan 31, 2025: Shares held short 40.60M
- Feb 14, 2025: Shares held short 42.30M
- Feb 28, 2025: Shares held short 45.06M
- Mar 14, 2025: Shares held short 46.88M
- Mar 31, 2025: Shares held short 49.80M
- Apr 15, 2025: Shares held short 56.31M
- Apr 30, 2025: Shares held short 60.22M
- May 15, 2025: Shares held short 67.27M
- May 30, 2025: Shares held short 65.86M
- Jun 13, 2025: Shares held short 63.56M
- Jun 30, 2025: Shares held short 65.59M
- Jul 15, 2025: Shares held short 66.24M
- Jul 31, 2025: Shares held short 63.02M
- Aug 15, 2025: Shares held short 62.83M
- Aug 29, 2025: Shares held short 59.84M
- Sep 15, 2025: Shares held short 63.31M
- Sep 30, 2025: Shares held short 64.34M
- Oct 15, 2025: Shares held short 65.04M
- Oct 31, 2025: Shares held short 63.66M
- Nov 14, 2025: Shares held short 64.36M
- Nov 28, 2025: Shares held short 68.08M
- Dec 15, 2025: Shares held short 69.68M
- Dec 31, 2025: Shares held short 68.32M
- Jan 15, 2026: Shares held short 70.27M
- Jan 30, 2026: Shares held short 71.51M
- Feb 13, 2026: Shares held short 71.34M
- Feb 27, 2026: Shares held short 70.23M
- Mar 13, 2026: Shares held short 66.19M
- Mar 31, 2026: Shares held short 60.65M
- Apr 15, 2026: Shares held short 59.44M
- Apr 30, 2026: Shares held short 58.31M
- May 15, 2026: Shares held short 58.07M
- May 29, 2026: Shares held short 57.81M
- Jun 15, 2026: Shares held short 58.66M
- Jun 30, 2026: Shares held short 53.19M
- Jul 15, 2026: Shares held short 52.40M
- Jul 31, 2026: Shares held short 49.77M
- Aug 14, 2026: Shares held short 52.81M
- Aug 31, 2026: Shares held short 39.15M
- Sep 15, 2026: Shares held short 32.87M
- Sep 30, 2026: Shares held short 30.86M
- Oct 15, 2026: Shares held short 32.60M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading55.0% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 55.0% of the shares in the reported trades were short sales, against 63.8% in the 14 before.
- Last 14 sessionsNov 2, 2026 – Nov 19, 2026
- 55.0%
- The 14 beforeOct 13, 2026 – Oct 30, 2026
- 63.8%
- Change
- -8.8 pts
- Short sales a dayon average, of 4.48M shares
- 2.46M
- More than atof 3,666 US-listed companies, same days
- 67%
- Median of alleight in ten from 34.5% to 63.8%
- 50.4%
- Short sales
- Oct 13, 2026: Short sales 64.8%
- Oct 14, 2026: Short sales 64.8%
- Oct 15, 2026: Short sales 67.3%
- Oct 16, 2026: Short sales 66.2%
- Oct 19, 2026: Short sales 71.1%
- Oct 20, 2026: Short sales 68.4%
- Oct 21, 2026: Short sales 70.2%
- Oct 22, 2026: Short sales 64.5%
- Oct 23, 2026: Short sales 60.1%
- Oct 26, 2026: Short sales 64.6%
- Oct 27, 2026: Short sales 57.1%
- Oct 28, 2026: Short sales 54.7%
- Oct 29, 2026: Short sales 52.5%
- Oct 30, 2026: Short sales 55.8%
- Nov 2, 2026: Short sales 56.4%
- Nov 3, 2026: Short sales 62.5%
- Nov 4, 2026: Short sales 60.1%
- Nov 5, 2026: Short sales 51.5%
- Nov 6, 2026: Short sales 59.7%
- Nov 9, 2026: Short sales 58.9%
- Nov 10, 2026: Short sales 51.8%
- Nov 11, 2026: Short sales 53.7%
- Nov 12, 2026: Short sales 58.6%
- Nov 13, 2026: Short sales 41.9%
- Nov 16, 2026: Short sales 46.6%
- Nov 17, 2026: Short sales 50%
- Nov 18, 2026: Short sales 48.4%
- Nov 19, 2026: Short sales 57.1%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Stephane BancelChief Executive OfficerDirectly13.01M
- Noubar AfeyanDirectorDirectly2.22M
- Stephen HogePresidentDirectly1.47M
- Paul SaganDirectorDirectly–
- Shannon Thyme KlingerChief Legal OfficerDirectly81.3K
- James M MockChief Financial OfficerDirectly60.1K
- Abbas HussainDirectorDirectly12.1K
- Arpa GarayChief Commercial OfficerDirectly3,690
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Stephane BancelChief Executive Officer | 13.01M | 9.21M | Aug 6, 2026 | Form 4 |
| Noubar AfeyanDirector | 2.22M | 3,924 | May 21, 2026 | Form 4 |
| Stephen HogePresident | 1.47M | – | Nov 17, 2026 | Form 4 |
| Paul SaganDirector | – | 312.0K | Mar 3, 2025 | Form 4 |
| Shannon Thyme KlingerChief Legal Officer | 81.3K | – | Sep 4, 2026 | Form 4 |
| James M MockChief Financial Officer | 60.1K | – | Oct 5, 2026 | Form 4 |
| Abbas HussainDirector | 12.1K | – | May 1, 2026 | Form 4 |
| Arpa GarayChief Commercial Officer | 3,690 | – | Dec 6, 2023 | Form 4 |
A lower bound: it counts only the 8 officers and directors with a market trade since Nov 21, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
10b5-1 trading plans
Since 2023 every 10-Q and 10-K says which insiders adopted or ended a trading plan (Rule 10b5-1) in the quarter: when, for how many shares, until when. A plan explains the sales that follow months before they show up on Form 4.
- Abbas HussaindirectorsWhat happenedAdoptedJun 15, 2026Shares2,930
- Stephen HogePresidentWhat happenedAdoptedJun 15, 2026Shares917.4K
- James MockChief Financial OfficerWhat happenedAdoptedJun 9, 2026Shares34.8K
- Shannon KlingerChief Legal OfficerWhat happenedAdoptedMay 5, 2026Shares31.8K
- Stephen HogePresidentWhat happenedAdoptedNov 13, 2025Shares320.0K
- Shannon KlingerChief Legal OfficerWhat happenedAdoptedSep 9, 2025Shares20.8K
- Abbas HussaindirectorsWhat happenedAdoptedSep 5, 2025Shares6,186
- Stéphane BancelChief Executive OfficerWhat happenedAdoptedSep 3, 2025Shares1.44M
- Abbas HussaindirectorsWhat happenedAdoptedMar 13, 2025Shares313
- Stephane BancelChief Executive OfficerWhat happenedEndedNov 8, 2024Shares150.0K
| Person | What happened | Until | Shares | Filing |
|---|---|---|---|---|
| Abbas Hussaindirectors | AdoptedJun 15, 2026 | Jun 11, 2027 | 2,930 | 10-Q |
| Stephen HogePresident | AdoptedJun 15, 2026 | Sep 17, 2027 | 917.4K | 10-Q |
| James MockChief Financial Officer | AdoptedJun 9, 2026 | Mar 1, 2027 | 34.8K | 10-Q |
| Shannon KlingerChief Legal Officer | AdoptedMay 5, 2026 | Sep 10, 2027 | 31.8K | 10-Q |
| Stephen HogePresident | AdoptedNov 13, 2025 | Aug 10, 2026 | 320.0K | 10-K |
| Shannon KlingerChief Legal Officer | AdoptedSep 9, 2025 | Sep 4, 2026 | 20.8K | 10-Q |
| Abbas Hussaindirectors | AdoptedSep 5, 2025 | Apr 30, 2026 | 6,186 | 10-Q |
| Stéphane BancelChief Executive Officer | AdoptedSep 3, 2025 | Aug 10, 2026 | 1.44M | 10-Q |
| Abbas Hussaindirectors | AdoptedMar 13, 2025 | Jun 30, 2025 | 313 | 10-Q |
| Stephane BancelChief Executive Officer | EndedNov 8, 2024 | – | 150.0K | 10-K |
As the company states them in Item 9B of the 10-K and Part II, Item 5 of the 10-Q, with structured data. A plan allows sales on preset dates and prices. It does not say whether all of them will be executed.
Executive pay
From the Pay versus Performance table every company puts in its proxy statement since 2023: what the chief executive was paid, what was actually paid once the shares vest at year-end values, and how the stock did against the peer group the company itself picked.
$20M
Actually paid: $16M
$9.8M
Actually paid: $6.4M
–
Total Revenue
$1.9B
From the proxy statement (DEF 14A) of Mar 16, 2026, as filed with the SEC with structured data. Pay in dollars. The company picks its own peer group and measure. DEF 14A
Share repurchases
How many of its own shares the company bought each quarter, at what average price, for how much, and what remains of the program its board authorized, from the table it puts in every 10-Q and 10-K.
- Dec 31, 202210-KAmount$402M
- Sep 30, 202210-QAmount$1.0B
- Jun 30, 202210-QAmount$1.3B
- Mar 31, 202210-QAmount$623M
- Dec 31, 202110-KAmount$857M
| Quarter | Shares | Average price | Amount | Left in the program | Filing |
|---|---|---|---|---|---|
| Dec 31, 202210-K | 3.20M | $125.57 | $402M | $2.8B | 10-K |
| Sep 30, 202210-Q | 7.12M | $141.35 | $1.0B | $3.2B | 10-Q |
| Jun 30, 202210-Q | 9.17M | $141.53 | $1.3B | $1.2B | 10-Q |
| Mar 31, 202210-Q | 3.82M | $163.21 | $623M | $2.5B | 10-Q |
| Dec 31, 202110-K | 3.49M | $245.76 | $857M | $143M | 10-K |
From the "Issuer Purchases of Equity Securities" table of the 10-Qs and 10-Ks, read without a model. Only the quarters whose shares times average price agree with the cash the company says it paid for repurchases in its cash-flow statement are shown. The shares include those withheld for officers' taxes. A quarter with an accelerated repurchase shows the table's shares and the cash paid, without an average price. 6 filing(s) not shown, as the table was not read or did not agree with the cash.
The shareholders' vote on pay
The advisory say-on-pay vote at each annual meeting, as the company states it in the 8-K it files after the meeting: how many voted for and against the executives' pay. 90% is the norm. Under 70% proxy advisers expect the board to respond the next year.
- 2026May 11, 2026For65.1%
- 2025May 5, 2025For77.3%
- 2024May 9, 2024For90.5%
- 2023May 5, 2023For87.9%
- 2022May 3, 2022For93.0%
- 2021Apr 29, 2021For92.9%
| Year | For | Votes for | Votes against | Abstentions | Broker non-votes | Filing |
|---|---|---|---|---|---|---|
| 2026May 11, 2026 | 65.1% | 169M | 90.76M | 440.1K | – | 8-K |
| 2025May 5, 2025 | 77.3% | 192M | 56.52M | 2.04M | – | 8-K |
| 2024May 9, 2024 | 90.5% | 248M | 25.92M | 488.3K | – | 8-K |
| 2023May 5, 2023 | 87.9% | 254M | 34.95M | 1.62M | – | 8-K |
| 2022May 3, 2022 | 93.0% | 278M | 20.99M | 442.0K | – | 8-K |
| 2021Apr 29, 2021 | 92.9% | 222M | 16.97M | 2.48M | – | 8-K |
From the 8-K (item 5.07) the company files after each annual meeting since 2021, read from the filing's text without a model. A company that votes every three years has empty years. The vote is advisory: the board is not bound by it.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- SPHBInvesco S&P 500 High Beta ETFWeight in the fund2.00%
- IBBiShares Biotechnology ETFWeight in the fund1.98%
- XBIState Street(R) SPDR(R) S&P(R) Biotech ETFWeight in the fund1.41%
- CGGRCapital Group Growth ETFWeight in the fund1.28%
- SCHMSchwab U.S. Mid-Cap ETFWeight in the fund0.92%
- LABUDirexion Daily S&P Biotech Bull 3X SharesWeight in the fund0.81%
- VHTVanguard Health Care Index FundWeight in the fund0.56%
- VBRVanguard Small-Cap Value Index FundWeight in the fund0.54%
- XLVState Street(R) Health Care Select Sector SPDR(R) ETFWeight in the fund0.43%
- FNDXSchwab Fundamental U.S. Large Company ETFWeight in the fund0.38%
45 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 647
- Q4 2025: Managers 677
- Q1 2026: Managers 731
- Q2 2026: Managers 784
Institutional investors by quarter
The fund managers holding MRNA, quarter by quarter, from Q3 2013 to Q2 2025, 45 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 784 managers held 319M shares, worth $22.3B. During the quarter 146 opened a position, 93 closed one, 254 added and 234 trimmed.
The largest holders, Q2 2026
- FMRIn the quarter+14%
- BlackRockIn the quarter+3.3%
- Vanguard Capital ManagementIn the quarter+1.5%
- Capital World InvestorsIn the quarter+19%
- Baillie GiffordIn the quarter-8.9%
- State StreetIn the quarter+5.8%
- Vanguard Portfolio ManagementIn the quarter-0.2%
- Geode Capital ManagementIn the quarter+2.9%
- Morgan StanleyIn the quarter+13%
- Theleme PartnersIn the quarter+0.1%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| FMR | 51.86M | +14% | $3.6B |
| BlackRock | 30.60M | +3.3% | $2.1B |
| Vanguard Capital Management | 23.21M | +1.5% | $1.6B |
| Capital World Investors | 22.28M | +19% | $1.6B |
| Baillie Gifford | 18.21M | -8.9% | $1.3B |
| State Street | 15.73M | +5.8% | $1.1B |
| Vanguard Portfolio Management | 15.58M | -0.2% | $1.1B |
| Geode Capital Management | 9.71M | +2.9% | $679M |
| Morgan Stanley | 9.54M | +13% | $668M |
| Theleme Partners | 8.06M | +0.1% | $564M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
The full analysis
What do Moderna's filings show?
Who buys and sells is one part of Moderna's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have MRNA's insiders bought or sold?
From May 29, 2026 to Nov 18, 2026 Moderna's insiders bought 0 and sold $86M of shares on the market. 100% of the sales were under set 10b5-1 plans.
Which well-known managers hold MRNA?
6 of the managers we track held the shares on Sep 30, 2026. The largest position was Millennium Mgmt (Englander)'s, worth $750M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.